This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of the products described within this website may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for each product in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
A Phase II Study of Afatinib in Patients with Previously Treated Advanced/Metastatic Urothelial Cancer with Genetic Alterations in ErbB Receptors
A Phase II, open-label trial to assess the anti-tumour activity and safety of afatinib* monotherapy after failure of platinum-based chemotherapy in patients with urothelial cancer with:
Trial CT.gov-Identifier: NCT02780687
Advanced/metastatic urothelial cancer with genetic alterations in ErbB receptors
Failure of platinum-based chemotherapy
No prior use of EGFR, ErbB2 or ErbB3 targeted treatment
Primary outcome measure:
Key secondary outcome measure:
Further secondary outcome measures:
Further outcome measures:
Currently recruiting participants; active in France, Italy and Spain.
Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/study/NCT02780687 (Accessed: March 2018).
*Afatinib is being investigated in urothelial cancer (UC) and head and neck squamous cell carcinoma (HNSCC) and is not approved for these uses. The efficacy and safety of afatinib in UC and HNSCC have not been established.
© 2018 Boehringer Ingelheim International GmbH. All rights reserved.
Last updated: July 2018
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue